Murali M. Chakinala

5.1k total citations
97 papers, 2.5k citations indexed

About

Murali M. Chakinala is a scholar working on Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine and Surgery. According to data from OpenAlex, Murali M. Chakinala has authored 97 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Pulmonary and Respiratory Medicine, 35 papers in Cardiology and Cardiovascular Medicine and 29 papers in Surgery. Recurrent topics in Murali M. Chakinala's work include Pulmonary Hypertension Research and Treatments (57 papers), Transplantation: Methods and Outcomes (23 papers) and Vascular Anomalies and Treatments (21 papers). Murali M. Chakinala is often cited by papers focused on Pulmonary Hypertension Research and Treatments (57 papers), Transplantation: Methods and Outcomes (23 papers) and Vascular Anomalies and Treatments (21 papers). Murali M. Chakinala collaborates with scholars based in United States, Canada and Germany. Murali M. Chakinala's co-authors include Elbert P. Trulock, Ramsey R. Hachem, G. Alexander Patterson, Roger D. Yusen, Michael Walter, Aviva Aloush, Thalachallour Mohanakumar, Anthony P. Khalifah, Bryan F. Meyers and John P. Lynch and has published in prestigious journals such as JAMA, Circulation and Journal of Clinical Investigation.

In The Last Decade

Murali M. Chakinala

93 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Murali M. Chakinala United States	28	1.3k	1.2k	583	537	452	97	2.5k
Jae Berm Park South Korea	27	1.2k 0.9×	459 0.4×	97 0.2×	540 1.0×	629 1.4×	204	2.5k
Michael A. Zimmerman United States	29	1.4k 1.1×	297 0.3×	140 0.2×	812 1.5×	225 0.5×	106	2.8k
Giampiero Palmieri Italy	23	556 0.4×	337 0.3×	237 0.4×	431 0.8×	107 0.2×	70	2.0k
Mark P. Steele United States	27	866 0.7×	1.6k 1.4×	70 0.1×	380 0.7×	238 0.5×	55	2.4k
Hilary J. Goldberg United States	28	904 0.7×	793 0.7×	56 0.1×	394 0.7×	404 0.9×	114	2.1k
L. Santambrogio Italy	28	811 0.6×	1.1k 0.9×	155 0.3×	161 0.3×	116 0.3×	106	2.4k
Aksel Foss Norway	34	2.5k 1.9×	757 0.6×	81 0.1×	1.1k 2.0×	834 1.8×	76	4.3k
Elizabeth Burke United States	19	989 0.7×	135 0.1×	295 0.5×	140 0.3×	678 1.5×	41	1.5k
M Alessiani Italy	25	1.4k 1.1×	247 0.2×	77 0.1×	258 0.5×	900 2.0×	112	2.6k
Suk‐Koo Lee South Korea	28	1.9k 1.4×	351 0.3×	68 0.1×	612 1.1×	276 0.6×	180	2.6k

Countries citing papers authored by Murali M. Chakinala

Since Specialization

Citations

This map shows the geographic impact of Murali M. Chakinala's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Murali M. Chakinala with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Murali M. Chakinala more than expected).

Fields of papers citing papers by Murali M. Chakinala

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Murali M. Chakinala. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Murali M. Chakinala. The network helps show where Murali M. Chakinala may publish in the future.

Co-authorship network of co-authors of Murali M. Chakinala

This figure shows the co-authorship network connecting the top 25 collaborators of Murali M. Chakinala. A scholar is included among the top collaborators of Murali M. Chakinala based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Murali M. Chakinala. Murali M. Chakinala is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ataya, Ali, James C. Coons, Meredith Broderick, et al.. (2025). Safety and pharmacokinetics of ralinepag, a novel oral prostacyclin receptor agonist. JHLT Open. 9. 100270–100270. 1 indexed citations

Kolaitis, Nicholas A., Jonathan Singer, Sonja Bartolome, et al.. (2025). The landscape of referrals for lung transplantation in pulmonary arterial hypertension: A report from the Pulmonary Hypertension Association Registry. The Journal of Heart and Lung Transplantation. 45(1). 125–136.

Farber, Harrison W., Murali M. Chakinala, Anna R. Hemnes, et al.. (2025). Characteristics of Patients with Pulmonary Arterial Hypertension Receiving Selexipag in the SPHERE Registry by Race and Ethnicity. Journal of Racial and Ethnic Health Disparities.

Chakinala, Murali M., et al.. (2025). Endothelial Heterogeneity in Pulmonary Hypertension. Arteriosclerosis Thrombosis and Vascular Biology. 46(1). 3–16.

Sahay, Sandeep, Murali M. Chakinala, Nick H. Kim, et al.. (2024). Contemporary Treatment of Pulmonary Arterial Hypertension: A U.S. Perspective. American Journal of Respiratory and Critical Care Medicine. 210(5). 581–592. 13 indexed citations

Kawut, Steven M., Rui Feng, Susan S. Ellenberg, et al.. (2024). Pulmonary Hypertension and Anastrozole (PHANTOM): A Randomized, Double-Blind, Placebo-Controlled Trial. American Journal of Respiratory and Critical Care Medicine. 210(9). 1143–1151. 14 indexed citations

Ataya, Ali, et al.. (2024). REAL-WORLD ORAL TREPROSTINIL INITIATIONS: INSIGHTS FROM SPECIALTY PHARMACY DATA. CHEST Journal. 166(4). A5824–A5826.

Gillies, Hunter, Murali M. Chakinala, Benjamin T. Dake, et al.. (2024). IMPAHCT: A randomized phase 2b/3 study of inhaled imatinib for pulmonary arterial hypertension. Pulmonary Circulation. 14(1). e12352–e12352. 5 indexed citations

McLaughlin, Vallerie V., Harrison W. Farber, Kristin B. Highland, et al.. (2023). Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry). The Journal of Heart and Lung Transplantation. 43(2). 272–283. 9 indexed citations

10.

Farber, Harrison W., Murali M. Chakinala, Michelle Cho, et al.. (2023). Characteristics of patients with pulmonary arterial hypertension from an innovative, comprehensive real‐world patient data repository. Pulmonary Circulation. 13(3). e12258–e12258. 3 indexed citations

11.

Garry, Jonah, Nicholas A. Kolaitis, Richard A. Kronmal, et al.. (2022). Anticoagulation in pulmonary arterial hypertension - association with mortality, healthcare utilization, and quality of life: The Pulmonary Hypertension Association Registry (PHAR). The Journal of Heart and Lung Transplantation. 41(12). 1808–1818. 5 indexed citations

12.

Ryan, John, Roham T. Zamanian, Ronald J. Oudiz, et al.. (2020). Care of patients with pulmonary arterial hypertension during the coronavirus (COVID‐19) pandemic. Pulmonary Circulation. 10(2). 1–7. 48 indexed citations

13.

White, Andrew J., Dewi Clark, Murali M. Chakinala, et al.. (2020). Genotype–Phenotype Correlations in Children with HHT. Journal of Clinical Medicine. 9(9). 2714–2714. 16 indexed citations

14.

Horn, Evelyn M., Murali M. Chakinala, Ronald J. Oudiz, Elizabeth Joseloff, & Erika B. Rosenzweig. (2020). Could pulmonary arterial hypertension patients be at a lower risk from severe COVID‐19?. Pulmonary Circulation. 10(2). 1–2. 45 indexed citations

15.

Horn, Evelyn M., Murali M. Chakinala, Ronald J. Oudiz, Elizabeth Joseloff, & Erika B. Rosenzweig. (2020). Author rebuttal to response regarding “Letter to the Editor regarding ‘Could pulmonary arterial hypertension patients be at lower risk from severe COVID‐19?’”. Pulmonary Circulation. 10(3). 1–2. 4 indexed citations

16.

White, R. James, Anton Vonk Noordegraaf, Stephan Rosenkranz, et al.. (2019). Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension. Respiratory Research. 20(1). 208–208. 17 indexed citations

17.

Le, Yan, Jin Y. Norris, Tonya Russell, et al.. (2006). IL-12 p80 Is an Innate Epithelial Cell Effector that Mediates Chronic Allograft Dysfunction. American Journal of Respiratory and Critical Care Medicine. 174(4). 461–470. 28 indexed citations

18.

Yusen, Roger D., Bryan F. Meyers, Murali M. Chakinala, et al.. (2006). Impact of Immediate Primary Lung Allograft Dysfunction on Bronchiolitis Obliterans Syndrome. American Journal of Respiratory and Critical Care Medicine. 175(5). 507–513. 273 indexed citations

19.

Khalifah, Anthony P., Ramsey R. Hachem, Murali M. Chakinala, et al.. (2004). Respiratory Viral Infections Are a Distinct Risk for Bronchiolitis Obliterans Syndrome and Death. American Journal of Respiratory and Critical Care Medicine. 170(2). 181–187. 251 indexed citations

20.

Hachem, Ramsey R., Murali M. Chakinala, Roger D. Yusen, et al.. (2003). The Predictive Value of Bronchiolitis Obliterans Syndrome Stage 0-p. American Journal of Respiratory and Critical Care Medicine. 169(4). 468–472. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact